At the request of Diamyd Medical AB, Diamyd Medical AB equity rights will be
traded on First North as from November 24, 2023.
Security name: Diamyd Medical AB TO 3 B
----------------------------------------
Short name: DMYD TO 3 B
----------------------------------------
ISIN code: SE0020356996
----------------------------------------
Orderbook ID: 312001
----------------------------------------
Terms: Issue price, 11 SEK per share
----------------------------------------------------------------------
2 option rights gives the right to subscribe for
1 new B- share in Diamyd Medical AB
----------------------------------------------------------------------
Subscription period: September 2, 2024 - September 30, 2024.
----------------------------------------------------------------------
Last trading day: September 25, 2024.
----------------------------------------------------------------------
Security name: Diamyd Medical AB TO 4 B
----------------------------------------
Short name: DMYD TO 4 B
----------------------------------------
ISIN code: SE0020357002
----------------------------------------
Orderbook ID: 312003
----------------------------------------
Terms: Issue price, 16 SEK per share
----------------------------------------------------------------------
2 option rights gives the right to subscribe for
1 new B- share in Diamyd Medical AB
----------------------------------------------------------------------
Subscription period: March 3, 2025 - March 31, 2025.
----------------------------------------------------------------------
Last trading day: March 26, 2025.
----------------------------------------------------------------------
This information is distributed at the request of the Certified Adviser, FNCA
Sweden AB. For further information, please call FNCA Sweden AB on +46 8 528 00
399.Nasdaq Stockholm AB: New equity rights for trading, Diamyd Medical AB (596/23)
© 2023 GlobeNewswire
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 18.04. | DIAMYD MEDICAL AB: Diamyd Medical announces final outcome in the company's rights issue | ||
| 16.04. | DIAMYD MEDICAL AB: Diamyd Medical announces preliminary outcome in the company's rights issue | ||
| 12.04. | Diamyd Medical AB: Recruitment milestone reached in Diamyd® Phase 3 trial | STOCKHOLM, April 12, 2024 /PRNewswire/ -- Diamyd Medical's precision medicine Phase 3 trial for Type 1 Diabetes, DIAGNODE-3, has enrolled 100 patients. To date, no serious adverse events... ► Artikel lesen | |
| 11.04. | DIAMYD MEDICAL AB: Diamyd Medical led ASSET innovation partnership organizes a workshop on the future treatment of Type 1 Diabetes | ||
| 05.04. | DIAMYD MEDICAL AB: Diamyd Medical's main Shareholders announce their subscription commitments in the ongoing rights issue |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen.
Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen,
bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen
Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu
verstehen sein kann.
